Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies 21h
Johnson & Johnson Receives FDA Approval for TRUFILL n?BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma 18 December
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* 12 December
